AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Finance Biggo

Published November 10, 2026

Biogen's lupus readouts, a strange psilocybin filing and biotech's rising political risk

Read the full story at Finance Biggo

Stifel therapeutics analyst Paul Matteis expects several of the biggest near-term catalysts in biotech to land in the next few quarters: Biogen's.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech